Trial Profile

Phase II Study Evaluating HSV-tk + Valacyclovir Gene Therapy in Combination With Androgen Deprivation Therapy, Brachytherapy, External Beam Radiotherapy, and Prostatectomy for High-Risk Prostate Cancer

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 22 Jan 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Aglatimagene besadenovec (Primary) ; Bicalutamide (Primary) ; Leuprorelin (Primary) ; Valaciclovir (Primary)
Indications Adenocarcinoma; Prostate cancer
Focus Therapeutic Use

13 Jan 2025 According to a Candel Therapeutics media release, company looking to report updated overall survival data for CAN-2409 from phase 2a clinical trial in pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC), expected in Q1 2025.
04 Jan 2019 According to a Candel Therapeutics media release, the company has received the Series B financing from PBM Capital Group, for Active Surveillance of this study.
24 Oct 2018 Status changed from not yet recruiting to recruiting.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com